Trial · NCT07889024
Multicomponent Exercise and Pain Science Education for Fall Prevention in Older Adults With Chronic Musculoskeletal Pain (MovePainFall)
NCT07889024, Not applicable, Not yet recruiting, Instituto Politécnico de Bragança
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Multicomponent Exercise and Pain Science Education for Fall Prevention in Older Adults With Chronic Musculoskeletal Pain (MovePainFall). Trials, record NCT07889024. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07889024
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Multicomponent Exercise and Pain Science Education for Fall Prevention in Older Adults With Chronic Musculoskeletal Pain (MovePainFall)
- NCT number
- NCT07889024
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Instituto Politécnico de Bragança
- Conditions
- Chronic Pain, Musculoskeletal Pain, Accidental Falls, Fear of Falling
- Interventions
- MovePainFall multicomponent exercise programme, Pain science and fall-prevention education
- First posted
- 2026-10-22
- Last updated
- 2026-11-04
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recruitment rate | Recruitment period (approximately 2 weeks, before randomisation) | Number of participants recruited per month and proportion of the target sample (30-40 participants) recruited within the planned recruitment period. Pre-specified feasibility success criterion: \>=75% of the target sample recruited. Participant flow will be reported in a CONSORT 2025 flow diagram, adapted according to the CONSORT extension for pilot and feasibility trials. |
| Primary | Eligibility and consent rates | Recruitment period (approximately 2 weeks, before randomisation) | Proportion of screened individuals who are eligible, and proportion of eligible individuals who consent to participate and are randomised (%, with 95% confidence intervals). Reasons for ineligibility and refusal will be recorded. |
| Primary | Adherence to the intervention | During the 12-week intervention period | Percentage of scheduled sessions attended (36 exercise sessions and 12 education sessions), per participant and overall, in the intervention group. Pre-specified feasibility success criterion: mean attendance \>=70% of sessions. |
| Primary | Retention | From randomisation to post-intervention assessment (approximately 16 weeks, including a 2-week holiday break) | Proportion of randomised participants who complete the post-intervention assessment, and proportion of dropouts with reasons, in each group. Pre-specified feasibility success criterion: retention \>=80%. |
| Primary | Safety: adverse events | From the start of the intervention to post-intervention assessment (approximately 16 weeks) | Number, type and severity of adverse events, reported as counts and rates per participant and per session, recorded in a structured safety log. Pre-specified success criterion: no serious intervention-related adverse events. |
| Primary | Acceptability: Patient Global Impression of Change (PGIC) | Post-intervention (within 2 weeks after completion of the 12-week intervention) | Participant-rated global impression of change in pain and function attributable to the exercise programme on the 7-point PGIC (Portuguese version; 1 = no change/worse to 7 = a great deal better), complemented by a brief study-specific satisfaction and acceptability questionnaire on the programme components. |
| Secondary | Change in functional mobility: Timed Up and Go (TUG) | Baseline (before randomisation) and post-intervention (within 2 weeks after completion of the 12-week intervention) | Time (seconds) to rise from a chair, walk 3 m, turn 180 degrees, walk back and sit down. Lower values indicate better mobility. |
| Secondary | Change in dual-task mobility: TUG with cognitive task (TUG-DT) and dual-task cost | Baseline (before randomisation) and post-intervention (within 2 weeks after completion of the 12-week intervention) | TUG performed while serially subtracting 3 from a 3-digit number between 300 and 400 (seconds). Dual-task cost (%) = \[(TUG-DT - TUG single task) / TUG single task\] x 100; higher positive values indicate greater cognitive-motor interference. |
| Secondary | Change in lower-limb function: 30-second Chair Stand Test | Baseline (before randomisation) and post-intervention (within 2 weeks after completion of the 12-week intervention) | Number of complete sit-to-stand repetitions in 30 seconds. Higher values indicate better lower-limb function. |
| Secondary | Change in balance: Mini-BESTest | Baseline (before randomisation) and post-intervention (within 2 weeks after completion of the 12-week intervention) | European Portuguese Mini-BESTest, 14 items (anticipatory postural adjustments, reactive postural control, sensory orientation, dynamic gait), total score 0-28. Higher scores indicate better balance. |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07889024
GET https://conductscience.org/api/trials/v1/NCT07889024/registered